Login to Your Account



Financings Roundup

With Stock Rising, Anthera Prices $50M Offering for Lupus Program

By Trista Morrison


Monday, June 6, 2011
Although Anthera Pharmaceuticals Inc. already had sufficient funding to complete its ongoing Phase III trial with varespladib for acute coronary syndrome and its ongoing Phase II trial with blisibimod for lupus, the biotech raised $50 million in a public stock offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription